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doi:10.101Matched-Cohort Analysis of Autologous Hematopoietic
Cell Transplantation with Radioimmunotherapy versus
Total Body Irradiation–Based Conditioning for
Poor-Risk Diffuse Large Cell Lymphoma
Amrita Krishnan,1 Joycelynne M. Palmer,2 Ni-Chun Tsai,2
Jennifer R. Simpson,3 Auayporn Nademanee,1 Andrew Raubitschek,4
Sandra H. Thomas,1 Stephen J. Forman1We conducted a matched-cohort analysis of autologous transplant conditioning regimens for diffuse large
cell lymphoma in 92 patients treated with either radioimmunotherapy (RIT) or total body irradiation
(TBI)–based conditioning regimens. The RIT regimen consisted of 0.4 mCi/kg of 90Y-ibritumomab tiuxetan
plus BEAM (BCNU, etoposide, cytarabine, melphalan). The TBI-based regimen combined fractionated TBI
at 1200 cGy, with etoposide and cyclophosphamide. Five factors were matched between 46 patient pairs:
age at transplant 65 years, disease status at salvage, number of prior regimens, year of diagnosis 65 years,
and year of transplantation 65 years. Patients in the TBI group had higher rates of cardiac toxicity and mu-
cositis, whereas Z-BEAM patients had a higher incidence of pulmonary toxicity. Overall survival at 4 years
was 81.0% for the Z-BEAM and 52.7% for the TBI group (P 5 .01). The 4-year cumulative incidence of
relapse/progression was 40.4% and 42.1% for Z-BEAM and TBI, respectively (P5 .63). Nonrelapse mortality
was superior in the Z-BEAM group: 0% compared with 15.8% for TBI at 4 years (P\.01). Our data demon-
strate that RIT-based conditioning had a similar relapse incidence to TBI, with lower toxicity, resulting in im-
proved overall survival, particularly in patients with $2 prior regimens.
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Although the Parma trial established the use of
high-dose chemotherapy with autologous hemato-
poietic cell transplantation (AHCT) as superior to
conventional chemotherapy for relapsed chemotherapy-
sensitive diffuse large cell lymphoma (DLCL) [1],
relapsed disease remains the most common cause of
treatment failure. To address this problem, various
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6/j.bbmt.2011.07.016including the use of novel conditioning regimens and
posttransplantation immunotherapy with rituximab
[2]. The regimens that have been studied as part of
prospective clinical trials include: total body irradia-
tion (TBI) plus combination chemotherapy with
etoposide and cyclophosphamide [3], high-dose BEAM
(BCNU, etoposide, cytarabine, melphalan) [4], BEAC
(BCNU, etoposide, cytarabine, cyclophosphamide)
[1], and cyclophosphamide, BCNU, etoposide [5]. In
a comparative study of TBI/etoposide/cyclophospha-
mide versus cyclophosphamide, BCNU, etoposide,
the relapse rate is lower in patients treated with the
TBI-containing regimen [6]. An inverse relationship
between recurrence rates and radiation doses is dem-
onstrated in a phase III trial of 12-Gy TBI versus
15.75-Gy TBI; the relapse rate is lower in the higher
dose radiation cohort, but also results in higher treat-
ment-related mortality [7]. In addition, the toxicity as-
sociated with a TBI-based conditioning regimen often
precludes its use in older patients and even in some
younger patients, as TBI is associated with substantial
morbidity. AGEL/TAMOcooperative study ofDLCL
patients treated with a TBI-containing regimen shows441
442 Biol Blood Marrow Transplant 18:441-450, 2012A. Krishnan et al.a 2.5-fold higher (hazard) risk of death compared with
those treated with chemotherapy alone [8].
Radioimmunotherapy (RIT) has been explored as
ameans of harnessing the antitumor effects of radiation
while potentially reducing toxicity comparedwith frac-
tionated TBI. The use of targeted antibodies to deliver
radiation directly to the tumor and its microenviron-
ment is intended to spare critical organs, thereby allow-
ing treatment of older and more heavily pretreated
patients. Two different radiolabeled anti-CD20
antibodies have been used to treat B cell lymphomas:
iodine-131 (I131)-tositumomab (Bexxar) and
yttrium-90 (Y90)-ibritumomab tiuxetan (Zevalin).
We previously reported the results of a phase I/II trial
demonstrating the safety of combining standard dose
90Y-ibritumomab with high-dose BEAM followed by
autologous transplantation (Z-BEAM) [9]. The toxic-
ity profile was similar to high-dose BEAM alone and
the overall survival (OS) at 2 years was a promising
89.7% in the 20 DLCL patients. A randomized phase
II comparison of BEAM versus Z-BEAM conditioning
before autologous transplantation forDLCL, reported
at the 2010 American Society of HematologyMeeting,
suggests improvements in both OS and progression-
free survival (PFS) in the Z-BEAM arm [10]. However,
often assumed, it has never been demonstrated that
outcomes for autologous transplantation with the
90Y-ibritumomab Z-BEAM regimen are superior to
TBI-based autologous conditioning regimens. In this
study, we performed a comparative analysis of a con-
secutive case-series of DLCL patients prospectively
treated with Z-BEAM, who were matched to patients
receiving a TBI-based conditioning regimen. The
goal of this retrospective study was to evaluate the im-
pact of RIT-based conditioning on OS and PFS.PATIENTS AND METHODS
Patients
From January 1997 to January 2009, a matched se-
ries of 92 patients with DLCL (46 patients for each
conditioning regimen) underwent AHCT at the City
of Hope (COH); Z-BEAM patients were transplanted
from 2002 to 2009, TBI patients were transplanted
from 1997 to 2008. All DLCL patients treated on
2 phase I/II RIT trials with myeloablative BEAM
plus standard dose 90Y-ibritumomab tiuxetan
(Zevalin) were included in the analysis as part of the
Z-BEAM treatment group. DLCL TBI patients were
identified and paired/selected for analysis from a pro-
spective observational research transplant database
and were all treated based on a standard institutional
operating procedure for cyclophosphamide (Cy)-TBI-
VP-16 autologous transplantation. In situations where
more than 1 potential TBI patient was identified as
a potential pair for a Z-BEAM patient, the best-matched patient was selected. Patients were matched
on age (65 years), disease status at the time of salvage,
number of prior regimens, year of diagnosis (65
years), and year of transplantation (65 years). The
COH institutional review board approved the analysis
of these data. All pathology specimens were reviewed
by the COHDepartment of Hematopathology to con-
firm diagnosis before transplantation. Disease status
was confirmed by clinical assessment, including phys-
ical examination, laboratory evaluation, imaging by
computed tomography (CT) scans and nuclear imag-
ing, and bone marrow biopsies, as per COH patient
care standard operating procedures. Chemosensitivity
was defined as at least a partial remission (PR) to sal-
vage treatment, as determined by CT scanning, and re-
solution of all disease-related symptoms, which was
maintained for at least 4 weeks. The international
prognostic index score was calculated as per the Inter-
national non-Hodgkin Lymphoma Prognostic Factors
Project [11]. Patients in both treatment groups were
managed similarly with respect to organ function
screening, disease status assessments, and follow-up.
All patients were enrolled on prospective observational
and long-term follow-up protocols.Eligibility Criteria
All patients
Patients with histologically confirmed CD201
DLCL were eligible if they met any of the following
conditions: (1) DLCL that required at least 2 different
induction regimens to achieve either complete or partial
remission, (2) high or high-intermediate age-adjusted
international prognostic index score at diagnosis, or
(3) experienced a relapse event after initial response.
Z-BEAM
Patient exclusion criteria included: prior RIT,
prior irradiation of .10 Gy to the liver or lung, and/
or active chronic hepatitis B or C. Organ function cri-
teria was standard for AHCT. In addition, patients had
to have\10% lymphomatous marrow involvement at
the time of stem cell collection. After the initial trial
consent and screening, patients were also determined
to be ineligible if they were human anti-Zevalin anti-
body positive or if they had unfavorable biodistribu-
tion on pre-Zevalin imaging.
TBI
Patients between the ages of 18 and 65 years were
eligible. The minimum organ function criteria fol-
lowed institutional treatment guidelines for AHCT.
Patient exclusion was primarily based on performance
status, age, extent of prior radiation, and other comor-
bid conditions.
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Regimens
All patients
Salvage chemotherapy was given to debulk disease
and to determine chemosensitivity before AHCT.
Chemosensitivity was defined as at least a PR to sal-
vage treatment and resolution of all disease-related
symptoms (based on CT scan), which was maintained
for at least 4 weeks. Some patients received 1.5 to
2 g/m2 Cy as part of mobilization, followed by filgras-
tim 10 mg/kg. Other patients were mobilized with
filgrastim following debulking chemotherapy.
Z-BEAM
On day221, patients were given an infusion of rit-
uximab 250 mg/m2 followed by Indium-111-labeled
ibritumomab tiuxetan 185 MBq. Starting in May
2008, patientswere administered 250mg/m2 cold ritux-
imab only if their serum rituximab levels were below 10
mg/mL before administration of either the imaging or
treatment dose of radiolabeled antibody. Ten of 46 pa-
tients were accrued after May 2008 and had rituximab
levels drawn; 2 of those 10 received rituximab 250 mg/
m2 before the imaging dose, and 0 of 10 needed it
before the therapeutic dose. Imaging studies were per-
formed at 2, 24, 48, and 72 hours to determine the bio-
distribution of the Indium-111-labeled antibody. On
day214, patientswith favorable imagingwere given rit-
uximab 250 mg/m2 (except for those accrued after May
2008), followedby 90Y-ibritumomab tiuxetan14.8MBq
(0.4mCi/kg); the dose was capped at 40mCi.Oneweek
later, patients were admitted to the transplant unit and
received BEAM: BCNU 150 mg/m2 on days 27 and
26, etoposide 100 mg/m2 and cytarabine 100 mg/m2
twice a day on days 25 through 22, and melphalan
140 mg/m2 on day21. On day 0, autologous stem cells
were infused per institutional standard operatingproce-
dures and followed by filgrastim on day 15. All
Z-BEAM patients with the exception of 1 (n 5 45) re-
ceived rituximab therapy before transplantation.
TBI
For all patients, peripheral blood progenitor cells
were mobilized with filgrastim 10 mg/kg with either
Cy or debulking chemotherapy. Radiation was deliv-
ered as 3 daily fractions starting on day 28 to a total
dose of 1200 cGy. This was generally performed as an
outpatient. On day 24, patients were admitted to the
transplant unit and received etoposide 40 mg/kg, fol-
lowed by Cy 100 mg/kg on day22. Stem cells were in-
fused on day 0 followed by filgrastim on day 15. All
patients received antibacterial, antiviral, and antifungal
prophylaxis as per institutional standard operating pro-
cedures. Just over one-half, 67% (n 5 31), of the TBI
patients received prior rituximab therapy.Disease Assessment
Response criteria for this analysis were from the
International Working Group [12]. Complete re-
sponse (CR) was defined as the complete resolution
of all measurable disease, sustained for at least 4 weeks.
PR was defined as a 50% or more reduction in the
sum of the products of the diameters of all measurable
lesions. Induction failure was defined as failure to
achieve at least a PRwith first-line therapy, or progres-
sion from a CR or PR within 4 weeks of first-line treat-
ment. Relapse was defined as a clinical or radiologic
progression at least 4 weeks after an initial CR or PR
to first-line therapy.
Staging was performed at salvage chemotherapy,
before AHCT and posttransplantation at 100 days, 6
months, 12 months, 18 months, 24 months, and then
every year thereafter or as clinically indicated. Staging
included physical examination, complete blood
counts, basic biochemical profile including renal and
liver function tests, lactate dehydrogenase, chest
X-ray, CTs of the chest, abdomen, and pelvis, and uni-
lateral or bilateral bone marrow biopsy if indicated.Statistical Analysis
The primary endpoints were OS and PFS; second-
ary endpoints included: early/late toxicities/complica-
tions, nonrelapse mortality (NRM), and relapse/
progression (RP) incidence. Survival estimates were
calculated based on the Kaplan-Meier product-limit
method; 95% confidence intervals (CIs) were calcu-
lated using the logit transformation and the Green-
wood variance estimate [13]. Differences between
Kaplan-Meier curves were assessed by the log-rank
test. Patients who were alive at the time of analysis
were censored at the last contact date. OS was mea-
sured from transplantation to death from any cause.
PFS was defined as time from transplantation to recur-
rence, progression, or death. RP incidence was defined
as time from transplantation to recurrence or progres-
sion. NRM was measured from transplantation to
death from any cause other than disease relapse or dis-
ease progression. Cumulative incidence curves were
generated for NRM and RP in the competing risks set-
ting, given that death and RP events were in competi-
tion. The cumulative incidence of NRM and RP were
calculated using the method described by Gooley
et al. [14]; differences between cumulative incidence
curves in the presence of a competing risk were tested
using the Graymethod [15]. The significance of demo-
graphic and treatment features was assessed using strat-
ified survival analysis and univariate, multivariable Cox
proportional hazards regression analysis, or the corre-
sponding hazard analysis for competing risks [16,17].
Univariate and multivariable Cox regression
models were used to assess the impact of patient, dis-
ease, and treatment factors on OS and PFS. The
Table 1. Patient Characteristics
Variable
Z-BEAM
(N 5 46) n (%)
or Median (Range)
TBI
(N 5 46) n (%)
or Median (Range)
Patient gender, n (%)
Female 17 (37) 21 (46)
Male 29 (63) 25 (54)
Age at transplant (years),*
median (range)
56.5 (19-78) 53 (21-62)
Months from Dx to HCT,
median (range)
16.4 (0.6-130) 12.8 (3.7-104)
Months from first-line
therapy to HCT
14.9 (5.7-125) 12.1 (3.6-54)
Year of transplant,* median
(range)
2005 (2002-2009) 2001 (1997-2008)
Disease status at time of
salvage, n (%)
First CR 6 (13) 7 (15)
Frist PR 7 (15) 5 (11)
Induction failure 10 (22) 12 (26)
$1st Relapse 23 (50) 22 (48)
Chemosensitivity, n (%)
Resistant 14 (30) 8 (17)
Sensitive 32 (70) 38 (83)
444 Biol Blood Marrow Transplant 18:441-450, 2012A. Krishnan et al.factors studied were: disease status at the time of sal-
vage (1 CR/PR; induction failure, equal to or greater
than first relapse), bulky disease at diagnosis ($5 cm,
yes/no), bone marrow involvement at AHCT (yes/
no), number of prior regimens (.2, #2), CD34 count
(\ or $5.2  106 cell dose), treatment regimen (RIT
or TBI), and chemosensitive disease (yes/no). All cal-
culations were performed using SAS version 9.2
(SAS Institute, Cary, NC) or R 2.11.1. Generally, sta-
tistical significance was set at the P \ .05 level; all
P values were 2 sided. For multivariable Cox regres-
sion, factors shown to be significant at the P\ .10 level
univariately were included in the analysis. The data
were locked for analysis on March 31, 2010, (analytic
date). Modification of treatment-related effects by
number of regimens received before AHCT (#2,
.2) and chemosensitivity status (sensitive, resistant)
were evaluated by including interaction terms/stratifi-
cation factors in the regression model [18].Bone marrow involvement
at Dx, n (%)
No 33 (72) 35 (76)
Yes 9 (19) 10 (22)
Not available 4 (9) 1 (2)
Bulky disease at Dx, n (%)
No 11 (24) 4 (9)
Yes 26 (57) 28 (61)
Not available 9 (19) 14 (30)
CD34 Cell dose median
(range)
5.4 (2.5-37) 5.1 (1.3-30)
Number of prior regimens,*
median (range)
2 (1-7) 2 (1-5)
Prior rituximab
No 1 (2) 15 (33)
Yes 45 (98) 31 (67)
Salvage only 5 (11) 7 (15)
Induction† 40 (87) 24 (52)
Failed rituximab
at induction‡
30 (65) 20 (43)
Z-BEAM indicates BCNU, etoposide, cytarabine, melphalan; TBI, total-
body irradiation; Dx, diagnosis; HCT, hematopoietic cell transplantation;
CR, complete remission; PR, partial remission.
*Matched factors.
†Induction group indicates that all patients had rituximab induction, and
may also have had rituximab during salvage therapy.
‡Failed rituximab at induction includes all patients who failed induction
or relapsed within 1 year of diagnosis, and also had rituximab at
induction.RESULTS
Treatment Group Matching
Patient, disease, and treatment characteristics are
shown in Table 1. The median age of the Z-BEAM
cohort was 56 years (range: 19-78) and 53 years
(range: 21-62) for TBI patients. Although the groups
showed no statistical differences on the match factors:
age at transplantation (65 years), disease status at
salvage, number of prior regimens, year of diagnosis
(65 years), and year of transplantation (65 years);
the 2 groups did show slight differences (not statisti-
cally significant) in prevalence of the following fea-
tures: gender, chemosensitivity, bulky disease at
transplantation, median time from diagnosis to trans-
plantation, and median time from first-line therapy to
transplantation. Prior rituximab therapy in the
Z-BEAM group was significantly higher than in the
TBI group (P \ .01). Among the 92 patients, 76
patients had received prior rituximab: 45 Z-BEAM
patients and 31 TBI patients. Of those patients
receiving prior rituximab, we further stratified into
those patients who received ritumab for salvage ther-
apy only and those who received rituximab as part of
induction therapy (6 salvage therapy as well). In ad-
dition, 30 patients in the Z-BEAM and 20 in the TBI
groups had failed rituximab induction (relapsed
within 1 year of diagnosis). The breakdown of previ-
ous rituximab treatments is displayed in Table 1.Toxicity
Toxicity data for the first 100 days posttransplan-
tation are illustrated in Figure 1. There was notably
more cardiac toxicity in the TBI group, specifically
ventricular and supraventricular arrhythmias, aswell as more deaths attributable to cardiac disease.
There were 8 episodes of documented bacterial
infection in the Z-BEAM group and 11 in the TBI
group. The 100-day mortality was 0% in the
Z-BEAM group and 8.7% in the TBI group (4 of
46); of the 4 deaths in the TBI group, 3 were attribut-
able to disease progression and 1 to infection. Pa-
tients continue to be followed for other long-term
complications, including myelodysplasia and sec-
ondary malignancies as shown in Table 2. There
was 1 case of myelodysplasia in the Z-BEAM group,
and there were 2 cases of acute myelogenous leuke-
mia in the TBI group.
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Figure 1. Toxicities #100 days. The number of patients with grade 3
and above toxicity in the first 100 days is graphically depicted. Z-
BEAM patients are white bars, and TBI patients are black bars. Toxicities
are NCI CTC v3.0.
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The median length of follow-up was 59.9 months
(range: 11.3-128.7) for all surviving patients (n 5 60).
The median follow-up for the 37 Z-BEAM patients
was 51.0 months (range: 11.3-88.0) and 81.9 months
(12.5-128.7) for the 23 TBI patients. As of the analytic
date, there were 17 RP events in the Z-BEAM group
and 19 in the TBI group. In the Z-BEAM group, there
were 9 total deaths and 23 in the TBI group; causes of
death are listed in Table 3. OS for the Z-BEAM group
was significantly improved; 81% (95% CI: 68.8-88.8)
for Z-BEAM versus 52.7% (95% CI: 44.6-60.2) for
the TBI group at 4 years (P5 .01) (Figure 2A). There
was a trend toward improved PFS in the Z-BEAM
group 59.6% versus 42% for the TBI group (P 5Table 2. Long-TermToxicities >100Days Posttransplantation
Event
Z-BEAM
(N 5 46) n (%)
TBI
(N 5 46) n (%)
Grade $3
Overall* 18 (39)* 32 (70)*
Cardiac 3 4
Pulmonary 5 3
Hepatic 0 1
Mucositis 0 4
Infection 1 5
Bacterial 1 4
Viral 0 0
Fungal 0 1
Secondary malignancy
Acute myelogenous leukemia 0 2
Basal cell carcinoma 1 0
Myelodysplasia 1 0
Squamous cell carcinoma 2 0
Z-BEAM indicates BCNU, etoposide, cytarabine, melphalan; TBI, total
body irradiation.
All toxicities are NCI CTC v3.0.
*Fisher exact test, P 5 .006..10) (Figure 2B). Results to date show that a plateau
in PFS appears to have been achieved for both groups:
at 2.6 years in the Z-BEAM group and 3.9 years for the
TBI group. The poorer OS probability for the TBI co-
hort was primarily because of toxicity, with a 4-year
cumulative incidence of NRM of 0% for Z-BEAM
and 15.8% (95% CI: 8.0-31.3) for TBI (P \ .009)
(Figure 2C). The 4-year cumulative incidence of RP
was very similar for both groups, as seen in
Figure 2D, with 40.4 (95% CI: 27.7-59.0) for
Z-BEAM and 42.1 (95% CI: 29.8-59.4) for TBI.
Because the incidence of RP was similar for the 2
regimens, we decided to look at subsequent treatments
and outcomes in the patients who relapsed following
autologous transplantation. In the Z-BEAM group,
8 of 17 relapsed patients were living (4 of the 8 survivng
more than 3 years since relapse), whereas in the TBI
group, only 3 of 19 were still alive at the analytic date.
In the relapsed Z-BEAM (n 5 17) versus TBI patients
(n 5 19), use of rituximab for salvage posttransplanta-
tion was proportionally similar in the 2 groups: 8 of
17 for Z-BEAM and 9 of 19 for TBI. A higher propor-
tionofZ-BEAMpatientswere salvagedpostautologous
relapsewith agents such as gemcitabine (5 of 17 versus 3
of 19), lenalidomide (3 of 17 versus 0 of 19), bendamus-
tine (2 of 17 versus 0 of 19), and bortezomib (2 of 17
versus 0 of 19), with several receiving more than 1 of
the above-listed agents. Two of the Z-BEAM patients
were salvaged postautologous relapse using allogeneic
transplantation (both died), and 2 of the TBI patients
were also salvaged postautologous relapse with allo-
geneic transplantation (1 died).
Predictors of Improved Survival: Multivariable
Analysis
Using Cox regression modeling, we further evalu-
ated the independent effect of treatment group andTable 3. Relapse and Death Events
Variable
Z-BEAM
(N 5 46) n (%)
TBI (N 5 46)
n (%)
Number of relapse/progression
events
17 (37) 19 (41)
Number of death events 9 (20) 23 (50)
Cause of death
Relapse/disease progression 9 16
Infection 0 2
Chronic heart failure, chronic
renal insufficiency
0 1
Therapy-induced AML-related
CNS bleed
0 1
Hypertensive hypertrophic
cardiomyopathy with
diastolic dysfunction
0 1
Left hemispheric infarct,
autoimmune hemolytic
anemia, pneumonia
0 1
Unknown 0 1
Z-BEAM indicates BCNU, etoposide, cytarabine, melphalan; TBI, total
body irradiation; AML, acute myelogenous leukemia; CNS, central
nervous system.
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Figure 2. Survival outcomes stratified by treatment regimen. For all curves, solid lines represent Z-BEAM patients (N5 46) and dashed lines represent
TBI patients (N5 46). Panel A shows the Kaplan-Meier estimate of overall survival probability. Panel B shows progression-free survival, defined as time
from stem cell infusion to recurrence, progression, or death from any cause, whichever occurred first. Panel C shows the cumulative incidence of
nonrelapse mortality, and panel D shows the cumulative incidence of relapse or progression. RP and nonrelapse mortality were calculated as
competing risks.
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that were identified as predictive in the univariate anal-
ysis at the P# .10 level. ForOS, the factors found to be
predictive by univariate analysis were: treatment type
(2-fold increase in risk for TBI patients), disease status
at salvage (4- to 8-fold increase in risk for patients
beyond 1 CR/PR), number of prior regimens (2-fold
increase in risk for patients who received more than
2 regimens before AHCT), and prior rituximab ther-
apy (2-fold increase in risk for patients who did not
receive prior rituximab). Generally, the same list of
risk factors was identified for PFS, with the addition
of chemosensitivity status. Patients with resistant dis-
ease showed a 2-fold increase in RP or death when
compared with patients with sensitive disease.
In our univariate and initial multivariable analysis,
an interesting phenomenon occurred in which the im-
pact of treatment arm on hazard risk did not attain sig-
nificance in the univariate setting but was significant in
the multivariable analysis. This uncharacteristic result
prompted us to revise the Cox regression model to
include an interaction term, which tested for possible
interactions between treatment arm and other factors
in the analysis. A significant interaction effect was
seen between the variables of treatment arm and num-
ber of prior regimens (P\ .01) for both OS and PFS.
This interaction relationship was identified after strat-
ified analyses revealed that the effect of 1 of the vari-
ables differed depending on the level of the other
variable. As shown in Figure 3A and B, patients treated
with more than 2 prior regimens who underwent
AHCT using a TBI-based regimen had significantlypoorer PFS when compared with TBI patients who re-
ceived 2 or fewer regimens (P\ .01). This difference
was not seen in the Z-BEAM group. A similar interac-
tion trend (P 5 .07) was seen between the variables of
treatment regimen and chemosensitivity status, for
PFS but not for OS. When assessing the impact of
treatment in the context of patient chemosensitivity
status, the results showed that Z-BEAM patients who
were chemosensitive had improved PFS outcomes
when comparedwith those whowere resistant (P5 .02)
(Figure 3C). Among TBI patients, however, this was
not the case (P 5 .17) (Figure 3D); patients who were
chemosensitive did not show significantly improved
PFS over chemoresistant patients.
For OS, the multivariable model showed that, after
controlling for the relationship between transplantation
conditioning regimen and number of prior regimens,
TBI patients who receivedmore than 2 regimens before
AHCT were at a significantly increased risk for death
posttransplantation (hazard ratio [HR]: 3.46; 95% CI:
1.23-9.79) (P 5 .02) (Table 4). Patients who were clas-
sified as induction failures at AHCTwere found to have
a significant increase in risk of death posttransplanta-
tion compared with those in first CR or PR (HR:
6.66; 95% CI: 1.81-24.53) (P \ .01); this remained
true after adjusting for the impact of treatment group
and number of prior regimens. For PFS, the multivari-
able results trended similar to OS (Table 4). The mul-
tivariable model showed that, after controlling for the
relationship between treatment group and number of
prior regimens, TBI patients who received more than
2 regimens before AHCT had a trend toward increased
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Figure 3. Factors interactingwith treatment regimen for progression-free survival (PFS). Panel A shows the PFS for the 46Z-BEAMpatients stratified by
the number of prior regimens. Panel B shows the PFS for the 46 TBI patients stratified by the number of prior regimens. Panel C shows the PFS for the 46
Z-BEAM patients stratified by sensitivity to chemotherapy. Panel D shows the PFS for the 46 TBI patients stratified by sensitivity to chemotherapy.
Biol Blood Marrow Transplant 18:441-450, 2012 447RIT versus TBI Autologous Conditioning for DLCLrisk for RP or death posttransplantation (HR: 1.89;
95%CI: 0.84-4.29) (P\ .13). Patients who were classi-
fied as induction failures at AHCT were found to have
a significant increase in risk of death or RP posttrans-
plantation compared with those in first CR or PR
(HR: 5.08; 955% CI: 1.69-15.31) (P \ .01); this re-
mained true after adjusting for the impact of treatment
group and number of prior regimens.DISCUSSION
The last 20 years has seen a shift in research em-
phasis from standard radiotherapy and chemotherapy
regimens toward inclusion of less toxic biologic, im-
munologic, and targeted therapies. RIT combines
the potency of radiotherapy in the treatment of lym-Table 4. Multivariable Analysis: OS and PFS
Variable
Overall Survival
Hazard Ratio 95% CI
Treatment * prior regimens
RIT * #2 regimens 1.00 —
RIT * >2 regimens 0.62 0.16-2.38
TBI * #2 regimens 0.92 0.28-3.09
TBI * >2 regimens 3.46 1.23-9.79
Disease status at HCT
First CR/first PR 1.00 —
$1st relapse 3.20 0.87-11.72
Induction failure 6.66 1.81-24.53
Chemosensitive status
Sensitive NA NA
Resistant NA NA
OS indicates overall survival; PFS, progression-free survival; CI, confidence inte
remission; PR, partial remission. NA, not analyzed.
*Indicates interaction between terms.phoma, with the targeting capability and immunologic
potency of cell-type specific monoclonal antibodies.
90Y-ibritumomab tiuxetan is more effective as a sin-
gle-agent therapy than its unlabeled, monoclonal anti-
body counterpart, rituximab, for the treatment of
B cell lymphoma [19], and also increases the response
rate when combined with cyclophosphamide, Onco-
vin, and prednisone or prednisolone (CHOP) chemo-
therapy [20]. RIT agents utilizing yttrium-90 as
opposed to iodine-131 have potential advantages based
on: (1) the longer path length of the b-particle emis-
sion, allowing for cross-fire killing of nonantigen bear-
ing cells in the tumor microenvironment, and (2) the
lack of g-particle emissions that necessitate shielding
of the patient from family members and friends.
Standard-dose 90Y-ibritumomab tiuxetan can be
administered in the outpatient setting, and its ease ofProgression-Free Survival
P Value Hazard Ratio 95% CI P Value
— 1.00 — —
.49 0.46 0.17-1.26 .13
.90 0.62 0.24-1.62 .33
.02 1.89 0.84-4.29 .13
— 1.00 — —
.08 3.57 1.28-9.90 .01
<.01 5.08 1.69-15.31 <.01
NA 1.00 — —
NA 1.51 0.78-2.92 .22
rval; RIT, radioimmunotherapy; TBI, total body irradiation; CR, complete
448 Biol Blood Marrow Transplant 18:441-450, 2012A. Krishnan et al.use and exportability has made yttrium the isotope of
choice for RIT at COH.
Addition of rituximab to front-line treatment reg-
imens for DLCL has drastically improved responses
and survival [21,22], raising the 5-year event-free sur-
vival from 29% for CHOP to 47% for R-CHOP.
Those selected DLCL patients who do fail rituximab-
containing front-line therapy have poorer outcomes
following salvage therapy with autologous transplanta-
tation than patients who have never been exposed to
rituximab [23]. One potential method of improving
response and survival rates for autologous transplan-
tation in relapsed DLCL patients is incorporation of
radioimmunotherapy into the conditioning regimen.
Z-BEAM, the radioimmunotherapy plus chemo-
therapy conditioning regimen combining 90Y-ibritumo-
mab tiuxetan plus high-dose BEAM, is demonstrated
to be well tolerated and efficacious in the initial phase
I/II studies [9,24]. Median engraftment times in the
initial trials are similar to conventional conditioning
regimens. Rates of pulmonary and hepatic toxicity
are also low: 12% grade 3 hepatic and 7%
pulmonary toxicity [9]. Based on this initial data, we
have performed subsequent trials targeting pre-RIT
serum blood rituximab and have analyzed efficacy in
various histologies such as mantle cell, follicular, and
DLCL. Based on preliminary data in DLCL patients,
RIT-based conditioning had a particular benefit for
DLCL patients, whose response to salvage BEAM
plus autologous transplantation is reduced in the post-
rituximab era [23].
Our matched cohort analysis of DLCL patients
supports the efficacy of RIT-based conditioning with
Z-BEAM. The PFS (4-year 60%) and OS (4-year
81%) of Z-BEAM were similar to other RIT high-
dose therapy regimens. For instance, a phase II study
from the Nebraska group of 40 chemosensitive
DLCL patients yielded a 3-year PFS of 70% and
OS of 81% [25]. The toxicity profile was favorable,
especially considering that the cohort included older
patients.
Nonetheless, a major concern regarding novel
conditioning regimens is whether efficacy has been
sacrificed in the name of minimizing toxicity. Histori-
cally, radiation has been extensively used in lymphoma
conditioning, because of the radiosensitivity of the
disease. Use of fractionated radiation greatly reduced
toxicity, allowing the delivery of higher radiation
dosing in the context of TBI. However, pulmonary
toxicity, especially in older patients, remains a concern.
Overall, the incidence of pneumonitis after TBI-based
conditioning for lymphoma is 22% [26]. The long-
term toxicity of therapy-related myelodysplasia is
also an ongoing issue, as radiation is a known risk
factor for transplantation-related myodysplastic syn-
drome [27]. In many centers, such as our own, TBI
has fallen out of favor because of these toxicities, andnumerous novel therapies are under exploration.
Nonetheless, radiation-based conditioning remains
a treatment modality for young, high-risk patients in
many transplant centers, because of its long-term
record of efficacy.
This matched comparative analysis suggests that
the toxicity profile of TBI-based conditioning for au-
tologous transplantation may outweigh its purported
benefits. Cardiac toxicity was a major factor in the
TBI-treated group; given the relatively older age of
non-Hodgkin lymphoma patients, this is a major con-
cern. Considering the fact that pre-HCT chest
irradiation is a known risk factor for cardiovascular
complications [28], the lower cardiac toxicity in the
Z-BEAM population is particularly desirable. There
were a higher number of pulmonary events in the
Z-BEAM group, but most were not clinically signifi-
cant as they included coughing in 4 patients and
temporary hypoxia during stem cell infusion in 6;
2 patients had pneumonia and 1 pneumonitis that
could be attributable to the conditioning regimen. De-
spite a higher incidence of fever and neutropenia in the
Z-BEAM-treated group, survival was not affected. It is
possible the higher fever/neutropenia incidence was
because of discontinuation of levofloxacin prophylaxis
in 2005. Relapse and progression incidence was also
not significantly different between the 2 groups, sug-
gesting that RIT conditioning had equal disease con-
trol to TBI. Because follow-up on the TBI group is
longer than for the Z-BEAM group, it is possible
that the higher proportion of surviving relapsed pa-
tients in Z-BEAM compared with TBI (8 of 17 versus
3 of 19) may theoretically still die, bringing the OS
curves closer together. However, of the 8 surviving re-
lapsed patients in the Z-BEAM group, 4 of them have
survived beyond 3 years postrelapse and are therefore
beyond the high-risk period for disease recurrence.
Thus, the use of RIT-based conditioning harnesses
the efficacy of radiation while greatly reducing toxic-
ity; NRM was significantly lower for Z-BEAM at 0%
compared with 15.8% for TBI (P\ .009).
Our analysis of the interaction between treatment
type (Z-BEAM versus TBI) and number of regimens
before AHCT also highlights the potential efficacy of
Z-BEAM conditioning. Most striking were the vastly
better results in Z-BEAM patients treated with multi-
ple prior chemotherapy regimens (.2) compared
with similar patients treated with TBI. Although the
number of prior regimens did not impact OS for
Z-BEAM-treated patients, the TBI patients with ex-
tensive prior therapy had significantly worse outcomes.
This difference is likely attributable to the superior
NRMof the RIT conditioning regimen. If these results
are confirmed, patients with multiple prior regimens
may derive benefit from Z-BEAM autologous trans-
plantation and be spared the toxicity of allogeneic
transplantion. On the other hand, when patients were
Biol Blood Marrow Transplant 18:441-450, 2012 449RIT versus TBI Autologous Conditioning for DLCLstratified as chemosensitive versus resistant, PFS was
significantly different in the RIT group compared
with no difference in the TBI group. This suggests an
improved efficacy of Z-BEAM in chemosensitive pa-
tients; that is, the chemosensitive patients did strikingly
well, whereas for TBI-treated patients, one could say
both chemosensitive and chemoresistant patients did
poorly.
We are aware that this study has some caveats re-
lated to its nonrandomized nature; however, very few
physicians would be likely to enroll such high-risk pa-
tients to a randomized comparison of these 2 regimens.
Onemajor difference in the treatment groups is related
to an imbalance in the use of rituximab pretransplanta-
tion in the 2 treatment arms. Prior rituximab treatment
was far more prevalent in the Z-BEAM arm (45 pa-
tients) compared with the rituximab arm (31 patients).
Of those who received prior rituximab, there were 30
patients in the Z-BEAM arm who failed rituximab-
containing induction therapy, and 20 patients in the
TBI arm. Despite the negative prognostic impact of
rituximab failure indicated by the CORAL study
[23], the OS was better for Z-BEAM. Although more
patients in the Z-BEAM arm received prior rituximab
compared with the TBI arm (98% versus 67%), which
would appear to favor prognosis in the Z-BEAM
group, a larger percentage of the Z-BEAM patients
(65%) had failed rituximab induction compared with
TBI patients (43%), which puts the Z-BEAM arm at
a prognostic disadvantage. It is possible that if there
had been fewer rituximab failures in the Z-BEAM
arm, it would have had an even greater survival advan-
tage over TBI.
We have attempted to equalize asmany variables as
possible through factor matching, but there are some
apparent differences (all nonsignificant except for
rituximab-related) between the 2 treatment arms that
may confound our results. For instance, some chemo-
therapy agents in the TBI arm, specifically Cy, were
not used in the RIT arm, and could therefore contrib-
ute to the higher toxicity rates. Also, because TBI has
been less frequently used in the past 5 years, the cases
tend to be separated based on time, although we have
limited this difference to 5 years in matched cases. In
addition, the Z-BEAM patients were all treated on
protocol, whereas the TBI patients were not. How-
ever, our review of supportive care standard operating
procedures over the years included in the study does
not reveal significant differences, with 2 exceptions.
First was the cessation of routine levofloxacin prophy-
laxis in the Z-BEAM group, whichmay account for the
higher rate of febrile neutropenia in that group. Sec-
ond, many of the patients in the TBI arm were staged
using only a CT scan, whereas all Z-BEAM patients
were staged pretransplantation using a PET scan. De-
spite these issues, this study is as well controlled as pos-
sible and, we believe, affirms the assumption that RITprovides radiotherapy as effectively as TBI with less
morbidity.
The small randomized phase II study comparing
Zevalin-BEAM to BEAM shows a trend toward im-
proved PFS in the RIT arm based on a preliminary re-
port of the data [10]. Updates of this abstract,
presented orally at the American Society of Hematol-
ogy meeting, showed improvement in both OS and
PFS for the Z-BEAM arm by multivariable analysis,
providing support for a potential phase III study.
Our comparison of Z-BEAM with TBI conditioning
is another step toward the establishment of RIT condi-
tioning as a new standard of care for AHCT condition-
ing for non-Hodgkin lymphoma. We demonstrate
comparable efficacy of the 2 regimens, as evidenced
by similar relapse incidence, with decreased toxicity
and NRM for Z-BEAM.ACKNOWLEDGMENTS
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